Inhibítor plazminogénového aktivátora (PAI-1) a diabetes mellitus. II. PAI-1 pri inzulínrezistentných stavoch
[Plasminogen activator inhibitor (PAI-1) and diabetes mellitus. II. PAI-1 in insulin resistant conditions]
Jazyk slovenština Země Česko Médium print
Typ dokumentu anglický abstrakt, časopisecké články, práce podpořená grantem, přehledy
PubMed
9820087
- MeSH
- diabetes mellitus krev MeSH
- inhibitor aktivátoru plazminogenu 1 krev MeSH
- inzulinová rezistence * MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- anglický abstrakt MeSH
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- inhibitor aktivátoru plazminogenu 1 MeSH
Insulin resistance (IR) is associated with an elevated PAI-1 level and by correlation with insulin and triacylglycerol (TG) levels. While in IR non-diabetics this relationship is close, in patients with NIDDM the mutual relationship is less marked and there are other factors which raise the PAI-1 levels such as proinsulin, oxidation stress or cytokines. Therefore achievement of satisfactory metabolic control, reduction of insulin and TG levels need not be associated with normalization of PAI-1. As it is an independent risk factor of atherosclerosis, further examinations are necessary in order to differentiate in more detail the possible causes of its rising level in order to obtain a rational basis for effective therapy.